NO20012570D0 - Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer - Google Patents

Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer

Info

Publication number: NO20012570D0
Authority: NO; Norway
Prior art keywords: parp inhibitors; substituted benzimidazoles; benzimidazoles; substituted; parp
Prior art date: 1998-11-27

Application number

NO20012570A

Other languages

English (en)

Other versions

NO20012570L (no

Inventor

Wilfred Lubisch

Michael Kock

Thomas Hoeger

Sabine Schult

Roland Grandel

Reinhold Mueller

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-27

Filing date

2001-05-25

Publication date

2001-05-25

1999-04-12 Priority claimed from DE1999116460 external-priority patent/DE19916460B4/de

2001-05-25 Application filed by Basf Ag filed Critical Basf Ag

2001-05-25 Publication of NO20012570D0 publication Critical patent/NO20012570D0/no

2001-07-13 Publication of NO20012570L publication Critical patent/NO20012570L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20012570A 1998-11-27 2001-05-25 Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer NO20012570L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19854933		1998-11-27
DE1999116460 DE19916460B4 (de)	1999-04-12	1999-04-12	Substituierte Benzimidazole, deren Herstellung und Anwendung
PCT/EP1999/009004 WO2000032579A1 (de)	1998-11-27	1999-11-23	Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Publications (2)

Publication Number	Publication Date
NO20012570D0 true NO20012570D0 (no)	2001-05-25
NO20012570L NO20012570L (no)	2001-07-13

Family

ID=26050434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012570A NO20012570L (no)	1998-11-27	2001-05-25	Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer

Country Status (32)

Country	Link
US (2)	US6448271B1 (no)
EP (1)	EP1133477B1 (no)
JP (1)	JP3432800B2 (no)
KR (1)	KR100417779B1 (no)
CN (1)	CN1184208C (no)
AR (1)	AR021400A1 (no)
AT (1)	ATE259789T1 (no)
AU (1)	AU764216B2 (no)
BG (1)	BG65047B1 (no)
BR (1)	BR9915701A (no)
CA (1)	CA2352554C (no)
CZ (1)	CZ300148B6 (no)
DE (1)	DE59908600D1 (no)
DK (1)	DK1133477T3 (no)
ES (1)	ES2216625T3 (no)
HK (1)	HK1042084B (no)
HR (1)	HRP20010484B1 (no)
HU (1)	HUP0200749A3 (no)
IL (2)	IL143303A0 (no)
MY (1)	MY128488A (no)
NO (1)	NO20012570L (no)
NZ (1)	NZ511825A (no)
PL (1)	PL196367B1 (no)
PT (1)	PT1133477E (no)
RU (1)	RU2001117757A (no)
SI (1)	SI1133477T1 (no)
SK (1)	SK285529B6 (no)
TR (1)	TR200101498T2 (no)
TW (1)	TWI247741B (no)
UA (1)	UA61158C2 (no)
WO (1)	WO2000032579A1 (no)
ZA (1)	ZA200104118B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU765224B2 (en)	1998-11-03	2003-09-11	Basf Aktiengesellschaft	Substituted 2-phenylbenzimidazoles, the production thereof and their use
DE19920936A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (en) *	1999-09-17	2001-03-29	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole derivatives
EA005950B1 (ru)	2000-08-08	2005-08-25	Санофи-Авентис	Производные бензимидазола, их получение и терапевтическое применение
FR2812878B1 (fr) *	2000-08-08	2002-10-11	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr)	2000-11-23	2003-05-09	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) *	2000-11-23	2003-01-31	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
JPWO2002068407A1 (ja) *	2001-02-28	2004-06-24	山之内製薬株式会社	ベンゾイミダゾール化合物
NZ528835A (en)	2001-03-12	2005-05-27	Avanir Pharmaceuticals	Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20040242635A1 (en) *	2001-03-30	2004-12-02	Painter Rachel J.	Encapsulated dyes in cosmetic compositions
WO2003007959A1 (en) *	2001-07-16	2003-01-30	Fujisawa Pharmaceutical Co., Ltd.	Quinoxaline derivatives which have parp inhibitory action
DE50310378D1 (de)	2002-07-26	2008-10-02	Basf Plant Science Gmbh	Neue selektionsverfahren
WO2004014873A1 (ja) *	2002-08-09	2004-02-19	Kyorin Pharmaceutical Co., Ltd.	4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
TWI276631B (en)	2002-09-12	2007-03-21	Avanir Pharmaceuticals	Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en)	2002-09-12	2004-04-30	Avanir Pharmaceuticals	PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
AU2003301436A1 (en)	2002-10-17	2004-05-04	Amgen Inc.	Benzimidazole derivatives and their use as vanilloid receptor ligands
HU0301154D0 (en) *	2003-04-28	2003-07-28	Hideg Kalman Dr	Pharmaceutical composition
WO2006094976A2 (en)	2005-03-08	2006-09-14	Basf Plant Science Gmbh	Expression enhancing intron sequences
EP2457901A1 (en) *	2005-03-14	2012-05-30	High Point Pharmaceuticals, LLC	Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
WO2006110683A1 (en) *	2005-04-11	2006-10-19	Abbott Laboratories	2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) *	2005-04-11	2012-11-01	Abbott Lab	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2012200399B2 (en) *	2005-04-11	2013-07-11	Abbvie Ireland Unlimited Company	1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
RU2008100017A (ru) *	2005-06-10	2009-07-20	Бипар Сайенсиз, Инк. (Us)	Модуляторы parp и способ лечения рака
US7825543B2 (en)	2005-07-12	2010-11-02	Massachusetts Institute Of Technology	Wireless energy transfer
EP2306615B1 (en)	2005-07-12	2020-05-27	Massachusetts Institute of Technology (MIT)	Wireless non-radiative energy transfer
US7405227B2 (en) *	2005-07-18	2008-07-29	Bipar Sciences, Inc.	Treatment of cancer
ES2378692T3 (es)	2005-09-29	2012-04-17	Abbott Laboratories	Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posición 2 son potentes inhibidores de PARP
EP1779849A1 (en) *	2005-10-28	2007-05-02	Nikem Research S.R.L.	V-ATPase inhibitors for the treatment of septic shock
EP1966157B1 (en)	2005-11-15	2010-03-24	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20080293795A1 (en) *	2006-01-17	2008-11-27	Abbott Laboratories	Combination therapy with parp inhibitors
PT2338487E (pt) *	2006-01-17	2013-12-16	Abbvie Bahamas Ltd	Terapia de combinação com inibidores de parp
US20090029966A1 (en) *	2006-01-17	2009-01-29	Abbott Laboratories	Combination therapy with parp inhibitors
US20080146638A1 (en) *	2006-01-17	2008-06-19	Abbott Laboratories	Combination therapy with parp inhibitors
US20080280867A1 (en) *	2006-01-17	2008-11-13	Abbott Laboratories	Combination therapy with parp inhibitors
WO2007113596A1 (en) *	2006-04-03	2007-10-11	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2007131016A2 (en) *	2006-05-02	2007-11-15	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20070292883A1 (en) *	2006-06-12	2007-12-20	Ossovskaya Valeria S	Method of treating diseases with PARP inhibitors
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
EP2059498A4 (en) *	2006-09-05	2011-01-12	Bipar Sciences Inc	TREATMENT OF CANCER
EP2061479A4 (en) *	2006-09-05	2010-08-04	Bipar Sciences Inc	FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
EP2336120B1 (en)	2007-01-10	2014-07-16	MSD Italia S.r.l.	Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
KR101473207B1 (ko) *	2007-04-13	2014-12-16	밀레니엄 파머슈티컬스 인코퍼레이티드	Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
US8067613B2 (en) *	2007-07-16	2011-11-29	Abbott Laboratories	Benzimidazole poly(ADP ribose)polymerase inhibitors
US8138168B1 (en) *	2007-09-26	2012-03-20	Takeda Pharmaceutical Company Limited	Renin inhibitors
CN101821269B (zh) *	2007-10-12	2014-05-28	艾伯维巴哈马有限公司	2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
KR20100102607A (ko) *	2007-11-12	2010-09-24	바이파 사이언스 인코포레이티드	Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
EP2217227B1 (en) *	2007-11-12	2013-08-21	BiPar Sciences, Inc.	Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
RU2495035C2 (ru) *	2008-01-08	2013-10-10	Мерк Шарп Энд Домэ Лтд	Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида
WO2009100159A2 (en) *	2008-02-04	2009-08-13	Bipar Sciences, Inc.	Methods of diagnosing and treating parp-mediated diseases
WO2009099736A2 (en) *	2008-02-06	2009-08-13	Lead Therapeutics, Inc.	Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2010083199A1 (en) *	2009-01-19	2010-07-22	Abbott Laboratories	Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011002520A2 (en)	2009-07-02	2011-01-06	Angion Biomedica Corp.	Small molecule inhibitors of parp activity
WO2011064751A1 (en)	2009-11-27	2011-06-03	Basf Plant Science Company Gmbh	Chimeric endonucleases and uses thereof
DE112010004582T5 (de)	2009-11-27	2012-11-29	Basf Plant Science Company Gmbh	Optimierte Endonukleasen und Anwendungen davon
EP2504429B1 (en)	2009-11-27	2016-04-20	BASF Plant Science Company GmbH	Chimeric endonucleases and uses thereof
JP2013521255A (ja)	2010-03-04	2013-06-10	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	フルオロアルキル置換２−アミドベンズイミダゾールおよび植物中のストレス耐性を強化するためのその使用
US20140051737A1 (en) *	2011-05-10	2014-02-20	Universite Laval	Methods for the treatment and diagnostic of pulmonary arterial hypertension
EP2736896B1 (en) *	2011-07-26	2016-12-14	Nerviano Medical Sciences S.r.l.	3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
EP2561759A1 (en)	2011-08-26	2013-02-27	Bayer Cropscience AG	Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh)	2011-11-30	2015-01-14	成都地奥制药集团有限公司	一种多聚(adp-核糖)聚合酶抑制剂
CN102617502A (zh) *	2012-03-19	2012-08-01	江苏先声药物研究有限公司	一类苯并噁唑衍生物及其医药应用
US20150216168A1 (en) *	2012-09-05	2015-08-06	Bayer Cropscience Ag	Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
GB201223265D0 (en) *	2012-12-21	2013-02-06	Selvita Sa	Novel benzimidazole derivatives as kinase inhibitors
CN104230898B (zh) *	2013-06-17	2016-06-29	上海汇伦生命科技有限公司	苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230897B (zh) *	2013-06-17	2016-07-06	上海汇伦生命科技有限公司	苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN103483322A (zh) *	2013-08-21	2014-01-01	中国药科大学	5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途
CN103396405A (zh) *	2013-08-21	2013-11-20	中国药科大学	具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
WO2018022851A1 (en)	2016-07-28	2018-02-01	Mitobridge, Inc.	Methods of treating acute kidney injury
US11384081B2 (en)	2016-09-20	2022-07-12	Centre Leon Berard	Benzoimidazole derivatives as anticancer agents
EP3534957A1 (en)	2016-11-02	2019-09-11	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and parp inhibitors
CN109232540A (zh) *	2018-06-15	2019-01-18	深圳市坤健创新药物研究院	一种取代苯并咪唑衍生物及应用
CN108997320A (zh) *	2018-08-30	2018-12-14	深圳市坤健创新药物研究院	一种含氟取代苯并咪唑衍生物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1354554U (no)
US4093726A (en)	1976-12-02	1978-06-06	Abbott Laboratories	N-(2-benzimidazolyl)-piperazines
HUP9901092A3 (en) *	1995-08-02	2001-11-28	Univ Newcastle Ventures Ltd	Benzimidazole compounds and their pharmaceutical use
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US6001866A (en)	1995-10-05	1999-12-14	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5972980A (en)	1995-10-05	1999-10-26	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5830905A (en)	1996-03-29	1998-11-03	Viropharma Incorporated	Compounds, compositions and methods for treatment of hepatitis C
ES2124167B1 (es)	1996-06-04	1999-09-16	Espanola Prod Quimicos	Nuevos derivados del bencimidazol con actividad antihistaminica.
GB9702701D0 (en)	1997-02-01	1997-04-02	Univ Newcastle Ventures Ltd	Quinazolinone compounds
US6303627B1 (en)	1998-06-19	2001-10-16	Eli Lilly And Company	Inhibitors of serotonin reuptake

1999
- 1999-11-23 DK DK99964497T patent/DK1133477T3/da active
- 1999-11-23 CN CNB998151130A patent/CN1184208C/zh not_active Expired - Fee Related
- 1999-11-23 CA CA002352554A patent/CA2352554C/en not_active Expired - Fee Related
- 1999-11-23 PL PL347884A patent/PL196367B1/pl unknown
- 1999-11-23 SI SI9930543T patent/SI1133477T1/xx unknown
- 1999-11-23 AU AU30343/00A patent/AU764216B2/en not_active Ceased
- 1999-11-23 CZ CZ20011855A patent/CZ300148B6/cs not_active IP Right Cessation
- 1999-11-23 SK SK714-2001A patent/SK285529B6/sk not_active IP Right Cessation
- 1999-11-23 IL IL14330399A patent/IL143303A0/xx active IP Right Grant
- 1999-11-23 AT AT99964497T patent/ATE259789T1/de active
- 1999-11-23 HU HU0200749A patent/HUP0200749A3/hu unknown
- 1999-11-23 RU RU2001117757/04A patent/RU2001117757A/ru unknown
- 1999-11-23 WO PCT/EP1999/009004 patent/WO2000032579A1/de active IP Right Grant
- 1999-11-23 NZ NZ511825A patent/NZ511825A/en not_active IP Right Cessation
- 1999-11-23 BR BR9915701-2A patent/BR9915701A/pt not_active IP Right Cessation
- 1999-11-23 KR KR10-2001-7006611A patent/KR100417779B1/ko not_active IP Right Cessation
- 1999-11-23 ES ES99964497T patent/ES2216625T3/es not_active Expired - Lifetime
- 1999-11-23 DE DE59908600T patent/DE59908600D1/de not_active Expired - Lifetime
- 1999-11-23 US US09/856,686 patent/US6448271B1/en not_active Ceased
- 1999-11-23 US US10/935,683 patent/USRE39608E1/en not_active Expired - Lifetime
- 1999-11-23 PT PT99964497T patent/PT1133477E/pt unknown
- 1999-11-23 EP EP99964497A patent/EP1133477B1/de not_active Expired - Lifetime
- 1999-11-23 TR TR2001/01498T patent/TR200101498T2/xx unknown
- 1999-11-23 UA UA2001064494A patent/UA61158C2/uk unknown
- 1999-11-23 JP JP2000585221A patent/JP3432800B2/ja not_active Expired - Fee Related
- 1999-11-25 AR ARP990106011A patent/AR021400A1/es unknown
- 1999-11-26 TW TW088120715A patent/TWI247741B/zh not_active IP Right Cessation
- 1999-11-27 MY MYPI99005192A patent/MY128488A/en unknown
2001
- 2001-05-21 ZA ZA200104118A patent/ZA200104118B/xx unknown
- 2001-05-22 IL IL143303A patent/IL143303A/en not_active IP Right Cessation
- 2001-05-25 NO NO20012570A patent/NO20012570L/no not_active Application Discontinuation
- 2001-06-13 BG BG105596A patent/BG65047B1/bg unknown
- 2001-06-26 HR HR20010484A patent/HRP20010484B1/xx not_active IP Right Cessation
2002
- 2002-05-04 HK HK02103400.6A patent/HK1042084B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2216625T3 (es)	2004-10-16
IL143303A0 (en)	2002-04-21
RU2001117757A (ru)	2004-02-27
CZ20011855A3 (cs)	2001-08-15
US6448271B1 (en)	2002-09-10
HK1042084B (zh)	2005-09-02
CA2352554C (en)	2006-10-10
PL196367B1 (pl)	2007-12-31
EP1133477A1 (de)	2001-09-19
MY128488A (en)	2007-02-28
BG65047B1 (bg)	2007-01-31
SK7142001A3 (en)	2001-12-03
CN1184208C (zh)	2005-01-12
CZ300148B6 (cs)	2009-02-25
PL347884A1 (en)	2002-04-22
TR200101498T2 (tr)	2001-11-21
WO2000032579A1 (de)	2000-06-08
JP3432800B2 (ja)	2003-08-04
ATE259789T1 (de)	2004-03-15
JP2002531442A (ja)	2002-09-24
SI1133477T1 (en)	2004-06-30
PT1133477E (pt)	2004-06-30
CA2352554A1 (en)	2000-06-08
AU3034300A (en)	2000-06-19
KR100417779B1 (ko)	2004-02-05
HUP0200749A3 (en)	2003-03-28
HRP20010484B1 (en)	2010-08-31
HK1042084A1 (en)	2002-08-02
ZA200104118B (en)	2002-05-21
IL143303A (en)	2006-12-10
EP1133477B1 (de)	2004-02-18
AU764216B2 (en)	2003-08-14
DE59908600D1 (de)	2004-03-25
NZ511825A (en)	2003-08-29
AR021400A1 (es)	2002-07-17
BG105596A (en)	2002-02-28
CN1332731A (zh)	2002-01-23
TWI247741B (en)	2006-01-21
USRE39608E1 (en)	2007-05-01
BR9915701A (pt)	2001-08-14
KR20010080596A (ko)	2001-08-22
HUP0200749A2 (en)	2002-08-28
HRP20010484A2 (en)	2003-04-30
DK1133477T3 (da)	2004-06-21
NO20012570L (no)	2001-07-13
UA61158C2 (uk)	2003-11-17
SK285529B6 (sk)	2007-03-01

Publication	Publication Date	Title
NO20012570D0 (no)	2001-05-25	Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO991922D0 (no)	1999-04-22	Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO20013452D0 (no)	2001-07-12	Benzoheterocykler og deres anvendelse som MEK-inhibitorer
DK1268481T3 (da)	2008-05-05	Inaseinkibitorer som terapeutiske midler
DK1204649T3 (da)	2007-12-03	Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO20021253L (no)	2002-04-24	Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
DE60020259D1 (de)	2005-06-23	C-aryl-glucosid-sglt2-inhibitoren
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1251848T3 (da)	2004-10-18	Gyraseinhibitorer og anvendelse deraf
DZ3223A1 (fr)	2001-04-26	Inhibiteurs de tyrosine kinases
DK1170288T3 (da)	2004-11-29	Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1282611T3 (da)	2005-02-14	Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
NO20001323D0 (no)	2000-03-14	Dipeptid-apoptose inhibitorer og deres anvendelse
NO20005400D0 (no)	2000-10-26	Kinoloner anvendt som MRS-inhibitorer og baktericider
NO20025150D0 (no)	2002-10-25	2-acylindolderivater og deres anvendelse som antitumormidler
NO20032490L (no)	2003-07-22	Substituerte 2-anilin-benzimidazoler og deres anvendelse som NHE-inhibitorer
DK0989121T3 (da)	2005-12-12	Substituerede benzamider og deres anvendelse som immunmodulatorer
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
EE200100371A (et)	2002-02-15	Amidinobensüülamiini derivaadid ja nende kasutamine trombiini inhibiitoritena
NO995513D0 (no)	1999-11-11	N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
PT1189929E (pt)	2003-12-31	Inibidores do factor viia
ATE252547T1 (de)	2003-11-15	Matrixmetalloproteinaseinhibitoren
DK1214302T3 (da)	2004-02-16	Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere

Legal Events

Date	Code	Title	Description
2003-07-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application